The estimated Net Worth of Mark Rothera is at least $5.22 Millón dollars as of 24 May 2017. Mark Rothera owns over 2,000 units of PTC Therapeutics Inc stock worth over $1,088,758 and over the last 11 years Mark sold PTCT stock worth over $4,127,398.
Mark has made over 21 trades of the PTC Therapeutics Inc stock since 2013, according to the Form 4 filled with the SEC. Most recently Mark exercised 2,000 units of PTCT stock worth $21,700 on 24 May 2017.
The largest trade Mark's ever made was selling 35,000 units of PTC Therapeutics Inc stock on 23 February 2015 worth over $2,380,350. On average, Mark trades about 5,871 units every 59 days since 2013. As of 24 May 2017 Mark still owns at least 33,739 units of PTC Therapeutics Inc stock.
You can see the complete history of Mark Rothera stock trades at the bottom of the page.
Mark's mailing address filed with the SEC is C/O PTC THERAPEUTICS, INC., 100 CORPORATE COURT, SOUTH PLAINFIELD, NJ, 07080.
Over the last 12 years, insiders at PTC Therapeutics Inc have traded over $50,602,930 worth of PTC Therapeutics Inc stock and bought 3,730,934 units worth $57,374,337 . The most active insiders traders include Suisse/ Credit, Adam Koppel y Bioventures Cayman Ltd Hbm. On average, PTC Therapeutics Inc executives and independent directors trade stock every 16 days with the average trade being worth of $888,748. The most recent stock trade was executed by Pierre Gravier on 16 July 2024, trading 2,269 units of PTCT stock currently worth $77,191.
ptc is biopharmaceutical company focused on the discovery and development of orally-administered, proprietary small molecule drugs that target post-transcriptional control processes. while ptc’s discovery programs are directed at targets in multiple therapeutic areas, ptc is focusing particularly on the development and commercialization of treatments for orphan and ultra-orphan disorders. post-transcriptional control processes regulate the rate and timing of protein production and are essential to proper cellular function. ptc’s internally-discovered pipeline addresses multiple therapeutic areas, including neuromuscular disorders, oncology and infectious diseases. for more information on the company, please visit our website www.ptcbio.com.
PTC Therapeutics Inc executives and other stock owners filed with the SEC include: